Technology | April 10, 2013

MIM Software Releases MIM 6

The new software offers deformable registration


April 10, 2013 — MIM Software Inc. has announced its software release MIM 6 is now available. Users in all areas of medical imaging can benefit from tools for deformable evaluation and correction, magnetic resonance/computed tomography (MR/CT) deformable and automated series management.

Reg Refine — building off the Reg Reveal, which was the first and only environment for deformable quality assurance (QA) and reporting — Reg Refine takes a step forward by allowing clinicians to not only detect any areas where a deformation is less than optimal, but also to make corrections.

“Reg Refine’s unique ability to repeatedly perform deformable evaluation and correction has changed how deformable registration can be used for critical tasks,” said Jon Piper, MIM’s director of research and business development. “Now, virtually any pair of images can be registered to one another, and you can have complete confidence in the accuracy of the results.”

The Assistant has also introduced a new integrated control for automating series management.  Intuitive screen displays show in simple terms what is scheduled and what has already occurred.  Simple-to-use filters automatically direct actions by referencing digital imaging and communications in medicine (DICOM) tags, and easy-to-write rules can be time-based or event-based.  In addition, The Assistant interfaces directly with MIM Workflows, providing auto-contouring and atlas-based segmentation automatically on multiple series.

This software was introduced in April.

For more information:

Related Content

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform
Technology | Neuro Imaging | March 15, 2018
March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., ha
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
ContextVision Demonstrates VolarView and the Orthopedic Package at ECR 2018
Technology | Advanced Visualization | February 27, 2018
At this year’s European Congress of Radiology (ECR), Feb. 28-March 4 in Vienna, Austria, ContextVision will showcase...
Aidoc Introduces AI Solution for Whole-Body CT Scan Analysis
News | Artificial Intelligence | February 20, 2018
Deep learning startup company Aidoc announced what it calls the world’s first and only comprehensive, full-body...
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys...
Overlay Init